Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Savient reports positive interim data from open-label extension to phase III trials of Puricase

May 14, 2008

Recent patents disclose new agents for endocrine disorders

May 13, 2008

Bristol-Myers Squibb develops a novel and potent statin with reduced myotoxicity

May 13, 2008

Recent Japanese patent describes new treatment options for gout

May 9, 2008

Orexigen completes enrollment in NB-303 and NB-304 phase III clinical trials for Contrave

May 9, 2008

FDA accepts Osteologix's IND application for NB-S101 for osteoporosis

May 9, 2008

Sernova concludes successful pre-IND meeting with FDA for Sertolin in diabetes

May 9, 2008

Genzyme reports preliminary results for novel oral candidate for Gaucher's disease

May 8, 2008

LifeCycle reports positive data from phase II program for LCP-AtorFen in mixed dyslipidemia

May 8, 2008

DiaKine and Kinexum to jointly develop new combination therapy for type 1 diabetes

May 8, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...